History
The history shows the progress of the company and is not intended to promote or advertise any drugs.
| 2003 | June | Company establishment |
|---|---|---|
| 2004 | April | License agreement with Janssen (LUNABELL) License agreement with Teva in USA (NOBELZIN) |
| 2006 | May | Sales alliance with Fuji Pharma (LUNABELL) |
| 2007 | April | Sales alliance with Alfresa (NOBELZIN) |
| June | License agreement with Novatech in France (talc) | |
| July | Sales alliance with Nippon Shinyaku (LUNABELL) | |
| December | License agreement with Pfizer (fosphenytoin) | |
| 2008 | April | Launch of NOBELZIN for Wilson's disease |
| July | Launch of LUNABELL (mixed hormone) | |
| December | Launch of NOBELBAR for neonatal seizures and status epilepticus | |
| 2009 | March | License agreement with Eisai (carmustine wafer for intracranial implantation) |
| November | Opening of Osaka office | |
| 2010 | June | Opening of Tokyo, Nagoya, and Fukuoka offices |
| December | Additional indication of LUNABELL (functional dysmenorrhea) License agreement with Keocyt in France (streptozocin) |
|
| 2011 | March | Sales alliance with Eisai (Fostoin) |
| April | Opening of Sapporo office | |
| May | Opening of Sendai office Co-development agreement with Nippon Boehringer (anhydrous caffeine) |
|
| September | License agreement with Clinigen in UK (Foscavir, antiviral chemotherapeutic) | |
| 2012 | January | Approval transfer from AstraZeneca (Foscavir) Launch of Fostoin for status epilepticus and prevention of postoperative seizure, Co-promotion with Eisai Opening of Tokyo Distribution Center |
| February | Launch of Foscavir through direct sales | |
| June | License agreement with Pfizer (sirolimus) | |
| 2013 | January | Launch of GLIADEL for malignant glioma Approval transfer from MSD (INDACIN, COSMEGEN) |
| June | The 10th Anniversary Opening of Omiya and Yokohama offices |
|
| September | Launch of LUNABELL tablets ULD for dysmenorrhea Launch of Alabel oral 1.5 g (aminolevulinic acid) for diagnosis of malignant glioma |
|
| December | Approval transfer to Eisai (GLIADEL) Launch of Unitalc for malignant pleural effusion |
|
| 2014 | September | Collaboration with SRI International on endometriosis drug development |
| December | Launch of RAPALIMUS, world first drug for lymphangioleiomyomatosis (LAM) Launch of Respia for apnea of prematurity |
|
| 2015 | February | Launch of ZANOSAR for malignant tumor (gastroenteropancreatic neuroendocrine tumor) Launch of NOBELZIN tablets Received “the Japan Academic Society of Venture and Entrepreneurs Award” |
| October | Sirolimus received the first “SAKIGAKE” fast-track designation for drugs | |
| 2016 | February | Titanium Bridge received the first “SAKIGAKE” fast-track designation for medical devices |
| November | Marketing approval transferred to Clinigen KK (Foscavir) | |
| 2017 | February | Mr. Shiomura (Managing Director & CEO) won the Minister of Economic, Trade and Industry Prize at Japan Venture Awards 2017 |
| March | Additional indication for NOBELZIN (hypozincemia) | |
| 2018 | June | Launch of RAPALIMUS Gel for tuberous sclerosis-associated skin lesions |
| July | Launch of TITANBRIDGE for adductor spasmodic dysphonia | |
| October | Launch of JEMINA for dysmenorrhea | |
| 2019 | March | Relocation of Head Office from Nihonbashi-Kobunacho, Chuo-ku to Shinkawa, Chuo-ku |
| June | Nobelpharma America, LLC established | |
| December | Launch of RETYMPA for tympanic membrane perforation | |
| 2020 | May | Plusultra pharma GmbH established |
| June | Launch of Melatobel for sleep-onset difficulty associated with neurodevelopmental disorder in children | |
| September | Direct sales of Fostoin | |
| December | Jiangsu Nobelpharma Co., Ltd. established | |
| 2021 | Juiy | Communications Depertment established in Administrative Affairs & Corporate Planning Division Compliance Division established |
| September | Additional indication for RAPALIMUS (refractory lymphatic disease [lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham's disease, lymphangiectasia]) Vaccine Business Division established |
|
| December | Sales of anticonvulsant, Fostoin 750 mg, for Injection transferred from Eisai | |
| 2022 | January | Domestic Sales & Marketing Division reorganized |
| March | Additional indication for Unitalc (inoperable secondary intractable pneumothorax) Additional indication for LUNABELL (coordinating the timing of initiation of modulated ovarian stimulation in assisted reproductive technology) Additional indication for JEMINA (coordinating the timing of initiation of modulated ovarian stimulation in assisted reproductive technology) HYFTOR (sirolimus topical gel) approved by FDA Vaccine Business Division renamed to Bio Business Division |
|
| August | HYFTOR (sirolimus topical gel) launched in the US | |
| 2023 | February | Launch of NOBELZIN Granules 5% for Wilson's disease and hypozincemia Start of “Inclusive,” information site for daily lives of chiltren with intractable diseases |
| March | "Xian Luo Li" (sirolimus topical gel) approved in China | |
| April | Launch of Zinc Kit “ACCUREAD Zn” (in-vitro diagnostic) and general-purpose spectrophotometric analyzer “ACCUREAD” (medical device) | |
| May | HYFTOR (sirolimus topical gel) approved in EU | |
| September | HYFTOR (sirolimus topical gel) approved in United Kingdom | |
| October | Launch of HYFTOR (sirolimus 2 mg/g gel) in Europe | |
| November | Nobelpharma Received Chairperson’s Award in 2023 “Sukoyaka Family 21” (National Campaign for Maternal and Child Health) | |
| December | Launch of zinc acetate tablets 25 mg/50 mg “Nobel” (authorized generic) by Daito | |
| 2024 | January | Launch of Sirolimus Gel “Xian Luo Li” in China Additional Indication for “RAPALIMUS” (intractable vascular anomalies [hemangioendothelioma, tufted angioma, arteriovenous malformation, blue rubber bleb nevus syndrome, combined vascular malformation, Klippel-Trenaunay-Weber syndrome]) Launch of RAPALIMUS Granules 0.2% |
| February | Approval for zinc acetate granules 5%“Nobel” (authorized generic) obtained by Daito | |
| March | Approval of “Sargmalin for inhalation 250 µg” for autoimmune pulmonary alveolar proteinosis Approval of “ACENOBEL Sustained Release Tablet 500 mg” for distal myopathy with rimmed vacuole Approval of “Zintus Tablets 25 mg/50 mg” for hypozincemia |
|
| June | Launch of zinc acetate granules 5%“Nobel” (authorized generic) by Daito | |
| July | Launch of RAPALIMUS Granules 0.2% Launch of “Sargmalin for inhalation 250 µg” for autoimmune pulmonary alveolar proteinosis |
|
| August | Launch of “Zintus Tablets 25 mg/50 mg” for hypozincemia | |
| September | Marketing Approval for “Alabel Oral 1.5 g” Succeeded by SBI Pharma | |
| November | Anti-GM-CSF Antibody Detection Kit “KBM LineCheck APAP” Launched | |
| December | Launch of “ACENOBEL Sustained Release Tablet 500 mg” for Distal Myopathy with Rimmed Vacuoles |
|
| 2025 | January | HYFTOR 2 mg/g gel (sirolimus) accepted for use within NHSScotland Drug price for HYFTOR 2 mg/g gel (sirolimus) agreed in Germany |
| March | Approval of Melatobel Tablet 1 mg/2 mg for Pediatic, a melatonin receptor agonist that improves the sleep onset |